A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is application/pdf
.
Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers
2017
Cold Spring Harbor Perspectives in Medicine
KRAS is the most commonly mutated oncogene in human cancer. Most KRAS-mutant cancers depend on sustained expression and signaling of KRAS, thus making it a high-priority therapeutic target. Unfortunately, development of direct small molecule inhibitors of KRAS function has been challenging. An alternative therapeutic strategy for KRAS-mutant malignancies involves targeting codependent vulnerabilities or synthetic lethal partners that are preferentially essential in the setting of oncogenic
doi:10.1101/cshperspect.a031518
pmid:29101114
pmcid:PMC5990478
fatcat:lmvu3aihgrdtzerwhkbk2wmdta